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Abstract   
Major depressive disorder (MDD) is a psychiatric disorder that is characterized by long-lasting 
sadness, depressed mood and loss of pleasure in life activities. It is the most prevalent mental 
health problem in the West Bank, Palestine, affecting around 30% of Palestinians. Recent 
studies argue that MDD can result from disruption to particular hematological and 
immunological pathways. Only 30% of patients with MDD respond to pharmacological 
modalities for treating MDD, the most commonly used of which are selective serotonin 
reuptake inhibitors (SSRIs). Unfortunately, there are no tools that can help predict in advance 
which MDD patient will, or will not respond to SSRIs. The aim of this study is to investigate 
immunological and hematological markers that have the potential to a priori predict response 
to SSRI antidepressants in patients with MDD to provide the field of psychiatry with valuable 
tools to select the appropriate treatment for the appropriate patient. 
We recruited 8 medication-naïve patients with MDD from different psychiatric clinics in the 
West Bank, Palestine. These patients never received any form of treatment. Further, we tested 
8 matched healthy control subjects. Patients with MDD were tested twice; (1) at baseline, 
upon diagnosis with MDD, and (2) 4-6 weeks after receiving SSRI treatment (estimated time 
for clinical improvement). Patients were assigned to two groups according to their response to 
SSRI treatment: (1) SSRI-responders and (2) SSRI-non-responders. Healthy subjects were 
also tested twice, 4-6 weeks apart. A peripheral blood sample was collected using an EDTA 
tube (10 mL) from each subject per session to investigate the levels of the following 
cytokines: IL-2, IL-6, IL-10, IFN-γ, MIF as well as for CRP quantification using ELISA. 
Further, we prepared blood films manually and examined them to obtain a differential count of 
the white blood cells.  
Our results showed that SSRI-responders and SSRI non-responders show trending differences 
at baseline in both cytokine levels and cell counts. In particular, SSRI-responders show higher 
levels of both pro-inflammatory and anti-inflammatory cytokines. Conversely, non-responders 
showed relatively lower levels of pro-inflammatory and anti-inflammatory cytokines. 
Hematological markers differentiated patients with MDD from healthy controls with higher 
levels of lymphocytes and lower levels of neutrophils and eosinophils. After treatment, SSRI-
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responders, but not non-responders, showed a relative decrease in pro-inflammatory cytokines 
and lymphocytes.  
These results could present an initial signal for potential a priori molecular markers of 
response to SSRI in patients with MDD. With sufficient recruitment of patients, we anticipate 
that statistical classification models can produce significant differences between responders 
and non-responders using the immunological and hematological markers under investigation 
in this study. 
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Definitions 
Major depressive disorder: is a psychiatric disorder that is characterized by long-lasting 
sadness, depressed mood and loss of pleasure in life activities and it is the most prevalent 
mental health problem in the West Bank, Palestine, affecting around 30% of Palestinians  
Selective serotonin reuptake inhibitor: is the most commonly used pharmacological agents 
to treat MDD, which increases the synaptic availability of serotonin. 
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CHAPTER ONE 
INTRODUCTION AND LITERATURE REVIEW 
_________________________________________________________________ 
1.1 Major Depressive Disorder (MDD) 
1.1.1 Clinical significance and prevalence of MDD in Palestine 
MDD is a psychiatric disorder that is characterized by long-lasting sadness, depressed mood 
and loss of pleasure in life activities (Belmaker and Agam 2008). MDD is the most prevalent 
mental health problem in the West Bank, Palestine, affecting around 30% of Palestinians 
(Canetti, Galea et al. 2010, Madianos, Sarhan et al. 2012) . The pathophysiology of MDD is0 
not very well understood. MDD can result from disruption to the immunological pathways. 
Several studies found that MDD patients exhibit variations in the levels of cytokines; 
immunological molecules that drive and coordinate immune response (Myint, Leonard et al. 
2005, Lee and Kim 2006) Further, some studies showed that cytokine treatment in patients 
with malignancy and hepatic disorders may precipitate MDD-like symptoms (Horikawa, 
Yamazaki et al. 2003). On the other hand, Schiepers et al. as well showed that external or 
internal stress induces cytokine imbalance that plays a role in MDD symptom expression in 
vulnerable individuals (Schiepers, Wichers et al. 2005). Taken together, these findings suggest 
that MDD could potentially have an immune component. 
1.1.2 The cytokine hypothesis of MDD 
Several studies have shown that MDD patients exhibit variations in immune response. The 
immune response is mediated by cytokines that are messenger molecules produced mainly by 
monocytes, lymphocytes and activated glial cells. Cytokines include five different groups; 
interleukins, chemokines, tumor necrosis factors, interferons, and transforming growth factors 
(Jeon and Kim 2016). According to their activity; cytokines are divided into two groups: (1) 
Pro-inflammatory cytokines that are directly or indirectly involved in the inflammatory 
processes, such as interleukin one (IL-1), interleukin six (IL-6), and interferon gamma (IFN-
γ), and (2) Anti-inflammatory cytokines, such as interleukin four (IL-4), interleukin ten (IL-
10), that suppress the immune response by counteracting cellular activation as well as the 
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production of pro-inflammatory cytokines (Schiepers, Wichers et al. 2005). Therefore, pro-
inflammatory cytokines and anti-inflammatory cytokines interact to maintain balance in the 
immune response. The production of the pro-inflammatory cytokines by macrophages or 
monocytes is determined by the immune activity (Jeon and Kim 2016). 
One of the most widely accepted theories of the pathophysiology of MDD is the cytokine 
hypothesis of MDD. It proposes that the observed increased levels of pro-inflammatory 
cytokines, IL-1 and interleukin-2 (IL-2) in MDD patients correlate with the severity of MDD 
(Smith 1991). For example, Hauser et al. found that 33.3% of patients with hepatitis met the 
diagnostic criteria for MDD following initiation of interferon therapy (Hauser, Khosla et al. 
2002). Further, some cognitive characteristics of MDD are similar to the symptoms of 
cytokine-induced sickness and range from subtle attentional deficits and memory impairments 
to delirium and psychosis. These impairments are also known to be associated with cytokine 
treatment of malignancies and chronic infections, such as interferon alpha (IFN-α) and IL-
2 (Meyers 1999, Schiepers, Wichers et al. 2005). 
1.1.3 Immunological changes in MDD 
Increased levels of pro-inflammatory cytokines, such as IL-1, IL-2 and IL-6, by activated 
macrophages and IFN-γ by activated T-cells are observed in MDD patients (Myint, Leonard et 
al. 2005, Lee and Kim 2006). Musil et al. showed significantly elevated serum levels of the 
pro-inflammatory cytokine macrophage migration inhibitory factor (MIF) in patients with 
MDD (Musil, Schwarz et al. (2011)). However, there was no known mechanism of how MIF 
elicits its function on MDD (Leyton-Jaimes, Kahn et al. 2017). MIF blood levels were 
decreased by antidepressants in MDD patients as Cattaneo et al. showed (Cattaneo, Gennarelli 
et al. (2013)). Pro-inflammatory cytokines, such as IL-2, IL-6 and IFN-γ, may precipitate 
hyperactivity of the hypothalamic–pituitary–adrenal (HPA) axis by disturbing the negative 
feedback inhibition of circulating corticosteroids on the HPA axis (Sapolsky, Rivier et al. 
1987, Harbuz, Stephanou et al. 1992, Pauli, Linthorst et al. 1998, Jeon and Kim 2016). 
Activation of the HPA axis increases cortisol secretion from the adrenal cortex, which is 
inversely related to the production of pro-inflammatory cytokines leading to a surge in their 
plasma concentrations (Watkins, Nguyen et al. 1999). Aside from the impaired inhibitory 
feedback of cortisol on its own production, the inhibitory feedback mechanism of cytokine 
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levels against increased levels of cortisol is also impaired in patients with MDD. These 
impairments may be directly related to the etiology of MDD (Jeon and Kim 2016).  
Studies have shown that some patients who are treated with interferon fulfill the diagnostic 
criteria for MDD two months after the beginning of their treatment (Horikawa, Yamazaki et 
al. 2003). Another study showed that the increased levels of IL-6 and IFN-α are significantly 
associated with the severity of MDD symptoms (Capuron, Gumnick et al. 2002). These 
findings support the cytokine hypothesis of MDD which postulates that the severity of MDD 
correlates with the increased levels of pro-inflammatory cytokines, like IL-1 and IL-2 (Maes, 
Meltzer et al. 1995).  
1.1.4 Hematological changes in MDD 
Heightened immune activation in MDD includes an increasing number of circulating 
lymphocytes and phagocytic cells (Maes, Meltzer et al. 1995). Evidence suggests that MDD 
has been reliably associated with an absolute leukocytosis, a relative reduction in T-cell 
populations and low lymphocyte proliferative response to mitogen. Additionally, both MDD 
and acute/chronic stressors have been reliably related to reduced natural killer-cell function as 
well as increased CD4/CD8 cell ratios (Zorrilla, Luborsky et al. 2001, Tuglu, Kara et al. 
2003). Moreover, Tuglu et al. showed that the leukocyte count of MDD patients decreased 
after antidepressant treatment (Tuglu, Kara et al. 2003).  
1.2 Selective Serotonin Reuptake Inhibitors (SSRIs) 
1.2.1 Definition 
The monoamine hypothesis proposes that MDD results from decreased extracellular 
monoamines availability, especially serotonin (5-HT) and noradrenaline (Charney 1998). 
Selective serotonin reuptake inhibitors (SSRI), the most commonly used pharmacological 
agents to treat MDD, increases the synaptic availability of serotonin (Svenningsson, Kim et al. 
2013). 
Serotonin, which is a neuromodulator, plays a regulatory role in peripheral cytokine 
production through regulation of cortisol level. Cortisol secretion from the adrenal cortex 
increases by HPA axis activation, which is inversely related to the production of pro-
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inflammatory cytokines, such as interleukin one beta (IL-1β) (Watkins, Nguyen et al. 1999). 
In MDD, the inhibitory mechanism that regulates cortisol and cytokine secretion against 
increased levels of cortisol is impaired (Jeon and Kim 2016). Serotonin inhibits the secretion 
of corticotrophin-releasing-hormone in the hypothalamus which ultimately decreases cortisol 
secretion. Further, inhibition of adrenocorticotropic hormone release in the pituitary also 
results in reduction of cortisol production. Thus, SSRI can restore the negative feedback of 
cortisol that occurs in MDD and normalize HPA axis function by increasing serotonin 
availability.  
SSRI can also regulate the immune cell activity by acting as serotonin antagonists on the 
immune cells. Macrophages have a serotonin uptake system that is similar to the system in 
platelets; however, T- lymphocytes express serotonin receptors (5-HT1A and 5HT2A/2C) and 
high-affinity serotonin transporters. By blocking these receptors, and thus causing deficiencies 
in intracellular serotonin storage and increasing extracellular serotonin, SSRI can have a 
negative immuno-regulatory role in the immune cell activity (Calogero, Gallucci et al. 1988). 
 
1.2.2 SSRIs remediate immunological and hematological changes in MDD 
Studies have shown that both MDD and response to SSRIs can be mediated by hematological 
and immune cells and molecules, such as white blood cells and cytokines (Schiepers, Wichers 
et al. 2005). Treatment with SSRI remediates the increase or decrease in some white blood cell 
counts and cytokine levels in responders. For example, Kubera at al. found that SSRI (such as 
citalopram and sertraline), on one hand, inhibit the production of the pro-inflammatory 
cytokines, IL-1, IL-2, IL-6, tumor necrosis factor-alpha (TNF-α) and IFN-γ, that are increased 
in MDD patients (Kubera, Kenis et al. 2000). On the other hand, SSRI stimulate the 
production of IL-10, which is a negative immune-regulatory cytokine, which can normalize 
the levels of other cytokines (Kubera, Kenis et al. 2000). Likewise, many studies have shown 
that SSRIs, such as fluoxetine, restore T cell proliferation and the CD4/CD8 cell ratio to their 
normal levels in MDD patients (Frick, Rapanelli et al. 2009). Further, SSRIs decrease C-
reactive protein (CRP), and leukocyte count to normal levels in MDD patients six weeks after 
treatment (Tuglu, Kara et al. 2003).  
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1.2.3 Classification of MDD patients according to the response to SSRIs 
Many pharmacological antidepressants were developed to treat MDD. However, clinical trials 
have shown that only 30% of MDD patients respond to treatment with antidepressants 
(Howland 2008). Studies have shown that both MDD and response to SSRIs can be mediated 
by hematological and immune cells and molecules, such as white blood cells and cytokines 
(Schiepers, Wichers et al. 2005). However, treatment with SSRI does not normalize white 
blood cell counts and cytokine levels in non-responder patients with MDD. Previous studies 
have reported a clear implication of IL-2, IL-6 and IL-10 in MDD and response to SSRI. On 
the other hand, studies showed that non-depressed patients develop symptoms of depression 
when they receive IFN-γ treatment. Moreover, increased levels of some cytokines such as MIF 
were found in MDD patients without clearly knowing the rule of MIF in MDD. However, a 
little is known about the interaction of the immunological markers, cytokines, in MDD and/or 
response to SSRIs. 
1.3 Brief Description of the Study 
In this project, we aim to study white blood cell counts and certain cytokine levels in 
medication-naïve patients with MDD before and after treatment with SSRIs. In particular, we 
will investigate pro-inflammatory cytokines, including IL-2, IL-6, IFN-γ and macrophage 
MIF, and the anti-inflammatory cytokine IL-10. Normally, pro- and anti-inflammatory 
cytokines counteract for a balanced immune response (Figure1.1). Based on previous 
evidence, IL-1, IL-6 and IL-10 are involved in MDD and SRRI treatment. Moreover, 
treatment with cytokines like IFN-γ in non-depressed patients resulted in symptoms of 
depression. Likewise, elevated levels of MIF are associated with behavioral changes, 
including depressive symptoms. Nevertheless, the role of these cytokines and their interaction 
in MDD and response to SSRI is still not well clarified. We anticipate finding an imbalance 
among pro- and anti-inflammatory cytokines in MDD that might be normalized with SSRI 
treatment in responders, but not in non-responders (Figure1.2).Studying these specific markers 
that can a priori differentiate SSRI responders and non-responders will have a significant 
impact on our understanding of the pathophysiology of MDD and the mechanism of action of 
SSRI antidepressants (Edwards, Bosch et al. 2010, Bay-Richter, Janelidze et al. 2015). 
Further, this will provide the field of psychiatry with valuable clinical assessment tools that 
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can significantly advance patient-centric approaches in the treatment of MDD (Edwards, 
Bosch et al. 2010, Bay-Richter, Janelidze et al. 2015). 
 
 
 
Figure1.1: The inflammatory response in the peripheral immune system. Interleukin-2 
(IL-2), interleukin-6 (IL-6), interleukin-10 (IL-10), interferon gamma (IFN-γ), 
macrophage migration inhibitory factor (MIF), Th1: T-helper cell 1, Th2: T-helper cell 
2, NK: natural killer cell, dashed line: inhibition, continuous line: stimulation. 
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1.4 Problem Statement 
MDD is the most prevalent mental health problem in the West Bank, Palestine, affecting 
around 30% of Palestinians (Canetti, Galea et al. 2010, Madianos, Sarhan et al. 2012). Only 
30% of MDD patients respond to SSRIs. Currently, psychiatrists have no valid tools to predict 
who will or will not respond to treatment among MDD patients.  
1.5 Study Justification 
Unfortunately, clinicians cannot predict who will or will not respond to SSRI antidepressants. 
If, however, a simple blood test in MDD patients could differentiate those who are, or are not, 
Figure1.2: The expected inflammatory response in the peripheral immune 
system in MDD and SSRI response. Interleukin-2 (IL-2), interleukin-6 (IL-6), 
interleukin-10 (IL-10), interferon gamma (IFN-γ), macrophage migration 
inhibitory factor (MIF), Th1: T-helper cell 1, Th2: T-helper cell 2, NK: 
natural killer cell, dashed line: inhibition, continuous line: stimulation.  
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likely to respond to subsequent SSRI administration, this would (1) provide immediate clinical 
relevance, helping to identify those most likely to benefit from SSRIs, and (2) inform future 
drug discovery by characterizing molecular and neural mechanisms associated with SSRI non-
responders. This study will be the first to combine hematological (WBCs) and immunological 
(cytokines) markers in medication-naïve MDD patients to a priori predict response to SSRIs. 
This research can lead to clinically significant transformations of the field of psychiatry, which 
can ultimately improve treatment of MDD by translating emerging neuroscience knowledge 
into large-scale clinical trials and treatment protocols. Since only 30% of MDD patients 
receiving SSRIs show significant reduction in symptoms, it is of significant clinical 
importance to develop convenient diagnostic tools to a priori identify SSRI responders and 
non-responders.   
1.6 Research Hypothesis 
- IFN-γ and MIF, unlike IL-2, IL-6, and IL-10 could be potential immunological 
markers to a priori differentiate SSRI responders from non-responders in medication-
naïve patients with MDD given their regulatory effects that could modulate the 
production of other cytokines.  
- Counts of white blood cells that produce IFN-γ and MIF, namely monocytes and 
lymphocytes (T helper1) cells, could constitute hematological markers that a priori 
differentiate SSRI responders from non-responders in medication-naïve patients with 
MDD. 
 1.7 Study Questions 
- Could IFN-γ and MIF a priori differentiate SSRI responders from non-responders in 
medication-naïve patients with MDD? 
- Could monocyte and lymphocyte (T helper1) cell counts a priori differentiate SSRI 
responders from non-responders in medication-naïve patients with MDD? 
1.8 Study Goal 
- To identify hematological and immunological markers that can a priori predict 
response to SSRIs in medication-naïve patients with MDD. 
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 1.9 Study Objectives 
- To quantify IL-2, IL-6, IFN-γ, IL-10, and MIF in MDD patients at baseline 
(medication-naïve) and 4-6 weeks after receiving SSRIs. 
o These cytokines are the most widely implicated in MDD and response to 
SSRIs. Accordingly, we will use them as peripheral markers.  
- To quantify CRP in MDD patients to control for the effect of inflammation. 
- To determine the differential white blood cell counts (monocytes, lymphocytes, 
granulocytes; neutrophils, basophils, eosinophils) in patients with MDD before and 
after receiving SSRIs. 
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CHAPTER TWO 
RESEARCH METHODOLOGY 
_________________________________________________________________ 
2.1 Study Design and Framework 
2.1.1  Study Design: Longitudinal study design. 
2.1.2  Sample Type: Admission-based sample. 
2.1.3  Study Place: West Bank, Palestine. 
2.1.4  Study Time: August 2016 - October 2017. 
2.2 Study Population 
We tested patients with Major Depressive Disorder (MDD) recruited from psychiatric clinics 
in the West Bank, Palestine.  
2.3 Ethical Considerations 
This research was conducted according to the Declaration of Helsinki and approved by the Al-
Quds Ethics Committee. Written informed consent was obtained from all subjects before 
protocol-specified procedures were carried out. The approval letter is available upon request. 
2.4 Assessment Criteria Including Materials and Methods for Each Variable 
In this longitudinal study, we recruited 8 medication-naïve patients with MDD from different 
psychiatric clinics in the West Bank, Palestine. These patients never received any form of 
treatment. Further, 8 matched healthy control subjects were recruited for this study.  
Patients with MDD were tested twice; (1) At baseline session, upon diagnosis with MDD, and 
(2) 4-6 weeks after receiving SSRI treatment (estimated time for clinical improvement). 
Healthy subjects were also tested twice 4-6 weeks apart. A peripheral blood sample was 
collected using an EDTA tube (10 mL) from each subject per session. Each blood sample was 
used for several tests as follows: (1) blood film preparation: 1mL of the blood sample, within 
two hours, and (2) plasma: the rest of the EDTA blood sample was spun at 1000g for 10 
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minutes then the plasma was harvested and stored at -70°C for cytokine and quantitative CRP 
tests. 
2.5 Sample Testing Methods and Devices 
In this study, we are interested in the following cytokines: IL-2, IL-6, IL-10, IFN-γ, MIF as 
well as CRP quantification. To measure the levels of these analytes, we used enzyme-linked 
immune-sorbent assay (ELISA) kits. This is the most commonly used assay to quantify CRP 
and cytokine levels as reported in several studies of MDD (Maes, Meltzer et al. 1995) and 
SSRI antidepressants (Hernandez, Mendieta et al. 2008) on cytokine levels. To quantify 
cytokine results we used a semi-automated washer system device. For CRP results we used an 
automated ELISA device (NycoCard READER II). 
We prepared the blood films manually using appropriate glass slides. Then, we stained them 
using a rapid stain “RAPIHEM”. We examined the stained blood films using light microscopy 
in order to obtain the differential white blood cell count. Table2.1 below summarizes the 
materials and methods that we used. 
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Table 2.1: The Used Materials and Methods. 
 
2.6 Sample Processing 
The frozen plasma samples at -70°C were thawed at room temperature using tap water. 
Test Name  Materials Material manufacture  Method  Device  
Human IL-2 Cytokine Human IL-2 Mini TMB 
ELISA Development KIT  
PEPROTECH  ELISA Semi-automated washer 
system  
Human IL-6 Cytokine Human IL-6 Mini TMB 
ELISA Development KIT 
PEPROTECH ELISA Semi-automated washer 
system 
Human IFN-γ Cytokine Human IFN-γ  Mini ABTS 
ELISA Development KIT 
PEPROTECH ELISA Semi-automated washer 
system 
Human IL-10 Cytokine Human IL-10 Mini ABTS 
ELISA Development KIT 
PEPROTECH ELISA Semi-automated washer 
system 
Human MIF cytokine  MIF (Human ELISA Kit) BioVison ELISA Semi-automated washer 
system 
Quntitative CRP 
 
NycoCard CRP  Alere 
 
ELISA Aautomated ELISA 
device (NycoCard 
READER II) 
Blood Film - Glass Slides 
- Rapid stain 
“RAPIHEM” 
-   
Manually 
 
Light Microscopy 
Complementary 
materials 
- ELISA Buffer Kit 
(TMB) 
- ELISA Buffer Kit 
(ABTS) 
- Multi-channel 
pipette(8 channels, 
30-300 µl) 
- PEPROTECH 
 
- PEPROTECH 
 
- ThermoFisher 
Scientific 
- - 
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2.7 Test Protocols  
2.7.1 Human cytokine ELISA kits Protocol 
All samples were tested using ELISA kits for MIF, IFN-γ, IL-2, IL-6, and IL-10 cytokines 
according to the manufacturer instructions. 
2.7.2 Quantitative CRP Test Protocol 
In the first step, 5 µl of subject plasma were diluted in the provided diluent (borate buffer and 
detergents) in a specific tube by mixing them for 10 seconds. Then, 50 µl of the diluted sample 
were applied to the test device (a plastic device containing a membrane coated with 
monoclonal anti-CRP antibodies). The sample was allowed to soak into the membrane for 
approximately 30 seconds. One drop of the conjugate (monoclonal anti-CRP antibodies 
labeled with ultra-small gold particles) was added to the test device and was allowed to be 
soaked for approximately 30 seconds. After that, one drop of the washing solution (phosphate 
buffered NaCl solution and detergents) was added to the test device and was allowed to soak 
for 20 seconds. Finally, the results were read using the NycoCard READER II.   
2.7.3 Blood Film Preparation Protocol 
On a slide, 5 µl of EDTA blood sample was applied and appropriately spread. Then, the film 
was left to dry. The slide was stained using Rapid stain “RAPIHEM”. The prepared blood film 
was read a differential count of the white blood cells (eosinophils, basophils, neutrophils, 
monocytes, and lymphocytes) using a light microscopy. 
2.8 Data Analysis 
For analysis of the levels of cytokine and white blood cell data, we used mixed-model 
MANOVA where testing session (baseline, retest) is a within-subject variable, group 
(responder, non-responder, control) is a between-subject variable, and cytokine levels and 
white blood counts are the dependent variables. Further, we used the Kolomogorov-Smirnov 
test to examine normality of the dependent variables at both testing sessions. We used IBM© 
SPSS 20.0 to analyze the data. 
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CHAPTER THREE 
STUDY RESULTS 
_________________________________________________________________ 
For each subject at each testing session, we obtained 10 results; 5 immunological markers, and 
5 hematological markers.  We used the Kolomogorov-Smirnov test to examine normality of 
the dependent variables at both testing sessions.  Almost all variables were normally 
distributed except for eosinophil and basophil counts.  Hence, we decided to use parametric 
statistical tests to examine our data. 
We used a mixed-model MANOVA to analyze our data, with group (MDD responder, MDD 
non-responder, and HC) as the between-subject variable, blood markers and testing sessions as 
the within-subject variables, and immunological (MIF, IFN-γ, IL-2, IL-6, and IL-10) and 
hematological (eosinophils, basophils, neutrophils, monocytes, and lymphocytes) marker 
concentrations as dependent variables.  Multivariate tests revealed a significant effect of blood 
marker.  Univariate within-subject comparisons showed a significant effect of blood markers 
(F(8,104)=12.857, p<0.001, η2=0.497), a significant interaction between group and blood 
marker (F(8,104)=1.758, p=0.047, η2=0.201). Figure 3.1 (A-E) show concentrations of 
specific cytokines (MIF, IFN- γ, IL-2, IL-6, and IL-10 respectively) in the three tested groups 
at session 1 (week-0) and session 2 (week 4-6). Figure 3.2 (A-E) show absolute count of 
specific hematological markers (eosinophils, basophils, neutrophils, monocytes, and 
lymphocytes respectively) in the three tested groups at session 1 (week-0) and session 2 (week 
4-6).                                                      
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Figure3.1 (A-E):  The concentrations of specific cytokines (MIF, IFN- γ, IL-2, 
IL-6, and IL-10, respectively) in the three tested groups at session 1 (week-0) 
and session 2 (week 4-6). 
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Figure3.2 (A-E): The absolute count of specific hematological markers 
(eosinophils, basophils, neutrophils, monocytes, and lymphocytes, respectively) 
in the three tested groups at session 1 (week-0) and session 2 (week 4-6). 
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To investigate the interaction between group and blood marker, we used two mixed-model 
ANOVAs with group as the between-subject variable, testing session and type of blood 
markers as the within-subject variables, and blood marker concentrations as the dependent 
variables.  To protect the level of significance, we used a Bonferroni corrected experiment-
wise α=0.025.  ANOVAs did not show any significant effects, mainly due to the low number 
of subjects included in the models. Figure 3.3(A-C) illustrates concentrations of all cytokines 
in the three groups: SSRI responders, SSRI non-responders and healthy controls respectively. 
Figure3.4 (A-C) illustrates absolute count of all hematological markers in the three groups: 
SSRI responders, SSRI non-responders and healthy controls respectively.  
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Figure 3.3(A-C): The concentrations of all cytokines in the three groups: SSRI 
responders (A), SSRI non-responders (B) and healthy controls (C). 
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Figure 3.4(A-C):  The absolute count of all hematological markers in the three 
groups: SSRI responders (A), SSRI non-responders (B) and healthy controls (C). 
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CHAPTER FOUR 
DISCUSSION 
_________________________________________________________________ 
In this thesis, we investigated different pro- and anti-inflammatory cytokines as well as 
hematological markers in two groups: (1) patients with MDD and (2) healthy controls. Patients 
were tested as medication-naïve at baseline and after receiving SSRI antidepressants for 4-6 
weeks. Healthy subjects were tested and retested on a similar timeline. Our results show that 
there is a trending increase in pro-inflammatory cytokine levels and a decrease in the anti-
inflammatory cytokine levels in medication-naïve patients with MDD. However, the degree of 
increase or decrease varied between SSRI responders and non-responder both at baseline and 
after treatment with SSRI. Further, we found that the WBC differential counts differed 
between MDD responders and non-responders vs. healthy controls both at baseline and after 
treatment with SSRI. The concentrations of the quantitative CRP were in the reference range 
for all tested MDD patients and healthy controls, which might indicate that all cytokine level 
and cell count variations, did not result from a generalized inflammatory response. However, 
we acknowledge that this is a preliminary study with a small number of subjects. Therefore, it 
is currently difficult to draw clear conclusions about changes in cytokines and hematological 
markers in MDD and in response to treatment. 
4.1 Medication-Naïve MDD Patients 
Evidence suggests that MDD exhibited imbalanced interaction between the pro-inflammatory 
and the anti-inflammatory cytokines that may result from interruptions in the immunological 
pathways (Myint, Leonard et al. 2005, Lee and Kim 2006) (Lee & Kim, 2006). At baseline, all 
MDD patients (future responders and non-responders) showed high concentrations of the pro-
inflammatory cytokines in line with previous studies in the literature (Maes, Meltzer et al. 
1995, Capuron, Gumnick et al. 2002, Leyton-Jaimes, Kahn et al. 2017). Further, our findings 
indicate that, at baseline, cytokine concentrations in SSRI non-responders were lower than 
those of healthy controls and SSRI responders. In particular, this was clear in the 
concentrations of the pro-inflammatory cytokines IFN-γ, MIF, and IL-2. However, the 
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concentrations of IL-6 were lower in SSRI responders than those in SSRI non-responders at 
baseline (before treatment). Moreover, the concentrations of the anti-inflammatory cytokine 
IL-10 were lower in SSRI non-responders than SSRI responders and healthy controls. This 
corresponds with our hypothesis that anti-inflammatory cytokines, such as IL-10, could show 
a priori differences between responders and non-responder, given their role in normal immune 
response (Schiepers, Wichers et al. 2005). 
Previous research found that the immune activation in  MDD includes increasing number of 
white blood cells (Maes, Meltzer et al. 1995). Moreover, some studies showed that the white 
blood cell counts can change in the response to antidepressants in MDD patients (Schiepers, 
Wichers et al. 2005). In our results, replicating previous literature, the absolute lymphocyte 
count was higher in medication-naïve MDD patients than in healthy controls as expected 
(Maes, Meltzer et al. 1995). Overall, our results show that the level of cytokines in MDD 
patients at baseline may be different in SSRI responders compared to SSRI non-responders 
before starting treatment. There are no studies in the literature that differentiate MDD patients 
who are SSRI responders from those who are SSRI non-responders in the medication-naïve 
state. Figure 4.1 summarizes the cytokine levels in MDD patients at baseline session. 
4.2 On SSRI MDD Patients  
Normally, the pro-inflammatory cytokines interact with the anti-inflammatory cytokines to 
maintain a balance in the immune response. In other words, the production of the pro-
inflammatory cytokines by macrophages or monocytes is involved directly or indirectly in the 
inflammatory process. The anti-inflammatory cytokines are produced to suppress the immune 
response by counteracting cellular activation as well as the production of pro-inflammatory 
cytokines to maintain the immune response (Schiepers, Wichers et al. 2005). This is what is 
expected to occur in SSRI responders after receiving SSRI: an increase in the levels of anti-
inflammatory cytokines to counter act the increased levels of pro-inflammatory cytokines in 
MDD patients. 
 In this study, after 4-6 weeks of treatment with SSRI, IFN-γ and IL-2 levels did not change in 
SSRI responders versus SSRI non-responders. However, MIF levels were decreased in SSRI 
responders but not in SSRI non-responders. This finding is in line with those of Cattaneo et al. 
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(Cattaneo, Gennarelli et al. (2013)); however, our results are shown in medication naïve MDD 
patients while Cattaneo et al. did their study in off-medication MDD patients. IL-6 levels were 
decreased in both patient groups. However, IL-6 concentrations in SSRI responders were even 
lower than those in SSRI non-responders. The concentrations of the anti-inflammatory 
cytokine IL-10 were decreased in SSRI non-responders but did not change in SSRI 
responders. Kubera at al. showed that SSRI stimulate the production of IL-10, which can 
normalize the levels of other cytokines. They also found that SSRI prevent the production of 
the pro-inflammatory cytokines, IL-1, IL-2, IL-6, tumor necrosis factor-alpha and IFN-γ 
(Kubera, Kenis et al. 2000). In our results, however, we only observed a decrease in pro-
inflammatory cytokines MIF and IL-6 levels following SSRI administration. It might be the 
case that normalization of pro-inflammatory cytokines takes longer than normalization of 
clinical symptoms. Further, the limited number of subjects per group in our study limits our 
ability to reach concrete conclusions. Figure 4.2 summarizes cytokine level variations in MDD 
patients after 4-6 weeks of receiving SSRI. 
The lymphocyte count decreased only in SSRI responders 4-6 weeks after administration of 
SSRI. Frick et al. showed that SSRI restore T cell proliferation and the CD4/CD8 cell ratio to 
their normal levels in MDD patients (Frick, Rapanelli et al. 2009). However, SSRI non-
responders showed increased number of lymphocytes following SSRI administration. The 
monocyte counts increased in SSRI non-responders but they did not change in SSRI 
responders. The increase and/or decrease in the cell counts might be related to cytokine level 
modulation in MDD and in response to SSRI since lymphocytes and monocytes are implicated 
in the cytokines production. Figure 4.3 shows the variations that occurred in cell counts before 
and after SSRI treatment in MDD patients.    
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Figure4.1: Cytokines levels in MDD patients at baseline. Interleukin-2 (IL-2), 
interleukin-6 (IL-6), interleukin-10 (IL-10), interferon gamma (IFN-γ), macrophage 
migration inhibitory factor (MIF), Th1: T-helper cell 1, Th2: T-helper cell 2, NK: 
natural killer cell, dashed line: inhibition, continuous line: stimulation. 
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Figure4.2: Cytokines levels in MDD patients after 4-6 weeks of SSRI treatment. 
Interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-10 (IL-10), interferon gamma 
(IFN-γ), macrophage migration inhibitory factor (MIF), Th1: T-helper cell 1, Th2: T-
helper cell 2, NK: natural killer cell, dashed line: inhibition, continuous line: 
stimulation. 
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4.3 Limitations 
The major limitation in our study is the low number of recruited subjects. This limited our 
ability to make clear conclusions about the current findings. We anticipate that with a larger 
sample we will have sufficient statistical power to find significant differences and be able to 
use statistical classification models to a priori differentiate SSRI responders and non-
responders. Further, we only investigated a sample of cytokines implicated in MDD. There are 
many other cytokines implicated in MDD but were not included. Moreover, we tested MDD 
Figure4.3: Cell counts in MDD patients at baseline and after 4-6 weeks of SSRI 
treatment. Interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-10 (IL-10), interferon 
gamma (IFN-γ), macrophage migration inhibitory factor (MIF), Th1: T-helper cell 1, 
Th2: T-helper cell 2, NK: natural killer cell, dashed line: inhibition, continuous line: 
stimulation. 
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patients after careful recruitment and diagnosis. However, structural and functional changes 
that are associated with comorbidities in MDD patients (e.g. comorbid anxiety in 80% of 
patients) might also play a role in shaping our results. Also, we examined MDD as a uniform 
entity; however, many studies consider MDD to be a spectrum that encompasses a group of 
different disorders based on symptom clusters. Finally, we had limited access to molecular and 
neural data that could explain the potential difference between responders/non-responders. 
4.4 Conclusion and Future Directions 
In summary, the results are indicative that there is an implication of cytokines as well as WBC 
counts in MDD and in response to SSRI with a clear interaction between the pro- and the anti-
inflammatory components of the immune response. Future efforts will focus on increasing the 
sample are needed to support these results and to clarify the pathophysiology of the immune 
activity in MDD and the response to SSRI. A future study can investigate the effects of 
chronic treatment with SSRIs and other antidepressants on MDD patients as well as on 
cytokine levels. Further, we aim to study the effect of antidepressants at different time points, 
not only one, after treatment initiation in MDD patients. 
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ية من خلال جزيئات دراسة استجابة مرضى الاكتئاب السريري لمثبطات استرجاع السيروتونين الانتقائ
 معينة دموية مناعية و
 إعداد: رحمة يوسف سعيد النتشة.
 المشرف الأول: د محمد مصطفى حرزالله.
 المشرف المشارك: د محمود عبد الرحمن سرور.
 الملخص
٠ُعّزف الاوزئبة اٌضز٠زٞ عٍٝ أٔٗ اػطزاة ٔفضٟ ٠زظف ثطٛي فززح اٌحزْ، ٚاٌّزاط اٌّحجط، ثبلإػبفخ 
أزشبرًا فٟ اٌؼفخ اٌغزث١خ إٌٝ فمذ اٌٍذح ٚاٌضعبدح فٟ شزٝ ِٕبحٟ اٌح١بح. ٚ٘ٛ أوضز اٌّشبوً اٌظح١خ إٌفض١خ 
رعزجز ِضجطبد اصززعبع اٌض١زٚرٛٔ١ٓ  % ِٓ اٌشعت اٌفٍضط١ٕٟ.30فٍضط١ٓ، ح١ش ٠ؤصز عٍٝ ِب ٠مبرة -
% فمط ِٓ 30الأزمبئ١خ أوضز ِؼبداد الاوزئبة اٌّضزخذِخ ٌعلاط ِزػٝ الاوزئبة اٌضز٠زٞ، عٍُّب ثأ ّْ 
١ش ٕ٘بن أٞ أدٚاد أٚ فحٛطبد طج١خ لبدرح ِزػٝ الاوزئبة ٠ضزغ١جْٛ ٌٙذٖ اٌّؼبداد. حزٝ ا٢ْ، ٌ
عٍٝ اٌىشف عٓ إِىبٔ١خ اصزغبثخ ِز٠غ الاوزئبة ِٓ عذَ اصزغبثزٗ ٌّضجطبد اصززعبع اٌض١زٚرٛٔ١ٓ 
الأزمبئ١خ لجً اٌجذء فٟ اٌعلاط. فٟ ٘ذا اٌض١بق، طزحذ اٌعذ٠ذ ِٓ اٌذراصبد اٌضبثمخ إِىبٔ١خ حذٚس 
د ِٕبع١خ ٚخٍٛ٠خ داخً عضُ اٌّز٠غ. ٌذا، فٟ ٘ذٖ اٌذراصخ الاوزئبة اٌضز٠زٞ ٔز١غخ ٌخًٍ ِب فٟ ِضبرا
ٔٙذف إٌٝ دراصخ عز٠ئبد ِٕبع١خ ٚخٍٛ٠خ ِع١ٕخ لذ رّىٕٕب ِٓ ِعزفخ اٌّضزغ١ت ِٓ غ١ز اٌّضزغ١ت 
ٌّضجطبد اصززعبع اٌض١زرٛٔ١ٓ الأزمبئ١خ لجً أْ ٠جذأ اٌّز٠غ اٌعلاط، ِّب ٠ضًٙ عٍٝ اٌطج١ت اٌّخزض 
 ز٠غ إٌّبصت. اخز١بر اٌعلاط إٌّبصت ٌٍّ
شبرن فٟ ٘ذٖ اٌذراصخ صّبٔ١خ ِٓ ِزػٝ اوزئبة صز٠زٞ ِٓ ع١بداد ٔفض١خ ِخزٍفخ فٟ اٌؼفخ اٌغزث١خ ٌُٚ 
٠ىٓ أ ٌّ ِٓ اٌّزػٝ اٌّشبرو١ٓ لذ عٌٛظ ِٓ لجً لأعً الاوزئبة اٌضز٠زٞ. وّب شبرن فٟ ٘ذٖ اٌذراصخ 
ًِ) ِٓ  30ع١ٕبد دَ ( ُعّعذ ٔفش اٌعذد ِٓ الأشخبص الأطحبء اٌضٍ١ّ١ٓ ِٓ الاوزٕئبة اٌضز٠زٞ.
ِزػٝ الاوزئبة اٌّشبرو١ٓ عٕذ رشخ١ض اٌّزع ٚ ِزح أخزٜ ثعذ رٍم١ُٙ ِضجطبد اصززعبع 
اٌض١زٚرٛٔ١ٓ الأزمبئ١خ ثّذح أرثعخ إٌٝ صزخ أصبث١ع. ٚلذ ر ُّ رمض١ُ اٌّزػٝ إٌٝ ِضزغ١ج١ٓ ٌٍعلاط ٚغ١ز 
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ّحبء فمذ رُ أخذ ع١ٕبرُٙ فٟ اٌّزح الأٌٚٝ صُ ِضزغ١ج١ٓ حضت رم١١ُّٙ ثعذ فززح اٌعلاط. أِب اٌّشبروْٛ الأط
 ,2-LI ثعذ٘ب ثأرثعخ إٌٝ صزخ أصبث١ع. اصزخذِذ ٘ذٖ اٌع١ٕبد ٌم١بس رزاو١ز عز٠ئبد ِٕبع١خ ِخزبرح ٟٚ٘
، وّب ٚرُ عًّ أفلاَ اٌذَ ٌٍم١بَ ثعّذ   stik ASILEثبصزخذاَ   PRCٚ  FIM ,γ-NFI ,01-LI ,6-LI
 اٌخلا٠ب اٌج١ؼبء اٌزفظ١ٍ١خ. 
زد ٔزبئظ ٘ذٖ اٌذراصخ إِىبٔ١خ اٌزفز٠ك ث١ٓ ِزػٝ الاوزئبة اٌضز٠زٞ اٌّضزغ١ج١ٓ ٌّضجطبد اصززعبع أظٙ
اٌض١زٚرٛٔ١ٓ الأزمبئ١خ عٓ غ١ز اٌّضزغ١ج١ٓ لجً اٌجذء ثبٌعلاط، ثح١ش أظٙزد اٌذراصخ فزٚلبد ٚاػحخ 
اٌّضزغ١جْٛ ٌّضجطبد ثشىً خبص، أظٙز  ث١ُٕٙ ِٓ ح١ش رزاو١ز ثعغ اٌغز٠ئبد إٌّبع١خ ٚ أعذاد اٌخلا٠ب.
اصززعبع اٌض١زٚرٛٔ١ٓ الأزمبئ١خ رزاو١ز ِزرفعخ ٌٍغز٠ئبد إٌّبع١خ اٌّمبصخ فٟ ٘ذٖ اٌذراصخ ِمبرٔخ 
ثبٌززاو١ز اٌزٟ أظٙز٘ب غ١ز اٌّضزغ١ج١ٓ ٌّضجطبد اصززعبع اٌض١زٚرٛٔ١ٓ الأزمبئ١خ لجً اٌجذء ثبٌعلاط. وّب 
ٚعذد ألً  setycohpmylالأزمبئ١خ عذد أوجز ٌخلا٠ب ٚأظٙز اٌّضزغ١جْٛ ٌّضجطبد اصززعبع اٌض١زٚرٛٔ١ٓ 
ِمبرٔخ ِع غ١ز اٌّضزغ١ج١ٓ ٌّضجطبد اصززعبع اٌض١زٚرٛٔ١ٓ  slihponisoeٚ   slihportuenِٓ خلا٠ب 
الأزمبئ١خ لجً اٌعلاط. ثعذ اٌعلاط، اٌّضزغ١جْٛ فمط ٌّضجطبد اصززعبع اٌض١زٚرٛٔ١ٓ الأزمبئ١خ أظٙزاٚا 
 .setycohpmylأخفبػًب فٟ رزاو١ز ثعغ اٌغز٠ئبد إٌّبع١خ اٌّمبصخ فٟ ٘ذٖ اٌذراصخ ٚ عذد خلا٠ب 
خ رعطٟ إشبرح اٌٚ١خ فٟ اٌمذرح عٍٝ ِعزفخ إِىبٔ١خ الاصزغبثخ ِٓ عذِٙب عٕذ ِزػٝ ٔزبئظ ٘ذٖ اٌذراص
ٌزأو١ذ ٘ذٖ إٌزبئظ ٔحزبط   ٌّضجطبد اصززعبع اٌض١زٚرٛٔ١ٓ الأزمبئ١خ.الاوزئبة لجً اٌجذء ثبٌعلاط ثبصزخذاَ 
الاوزئبة حضت ٚثلا شه ٌٍّز٠ذ ِٓ اٌع١ٕبد ٚاٌّشبرو١ٓ، ٌىٓ ٘ذٖ أٚي دراصخ رحبٚي اٌزّ١١ز ث١ٓ ِزػٝ 
اصزغبثزُٙ ٌٍعلاط لجً ثذئٗ. ٔغبػ ٘ذٖ اٌذراصخ ص١ّىٓ الأطجبء ِٓ اخز١بر اٌعلاط إٌّبصت، ٚص١خزظز فززح 
ِٓ اٌعلاط غ١ز اٌّغذٞ ٌذٜ ِزػٝ الاوزئبة إْ وبٔٛا ِٓ غ١ز اٌّضزغ١ج١ٓ ٌّضجطبد اصززعبع 
 اٌض١زرٛٔ١ٓ الأزمبئ١خ.
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